<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="45497e1a-f081-4a81-8511-ab0734c911e6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BIZENGRIÂ® safely and effectively. See full prescribing information for BIZENGRI.<br/>BIZENGRI (zenocutuzumab-zbco) injection, for intravenous use <br/>Initial U.S. Approval: 2024
</title>
   <effectiveTime value="20250307"/>
   <setId root="203daea4-fc87-40a4-a92f-ba2351b16de1"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080709490" root="1.3.6.1.4.1.519.1"/>
            <name>Partner Therapeutics, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="435a5da6-49f4-44f1-b78c-57f54beb0adc"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241218"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71837-1000" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BIZENGRI</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Zenocutuzumab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE72RB1W1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Zenocutuzumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AE72RB1W1X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Zenocutuzumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine monohydrochloride monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>trehalose dihydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="18.75" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71837-1000-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71837-1000-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241204"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761352" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="68788bab-683e-47cf-b150-f34eafd3dae6"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: EMBRYO-FETAL TOXICITY
</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Embryo-Fetal Toxicity: Exposure to BIZENGRI during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception </content>
                     <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s19">5.4</linkHtml>), Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>, <linkHtml href="#s36">8.3</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: EMBRYO-FETAL TOXICITY</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Embryo-Fetal Toxicity: Exposure to BIZENGRI during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception </content>
                           <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s19">5.4</linkHtml>), Use on Specific Populations (<linkHtml href="#s27">8.1</linkHtml>, <linkHtml href="#s36">8.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="d1f12405-98b0-4d18-bb7a-a28cdb738157"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BIZENGRIÂ® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion with disease progression on or after prior systemic therapy.* (<linkHtml href="#s3">1.1</linkHtml>)</item>
                           <item>Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion with disease progression on or after prior systemic therapy.* (<linkHtml href="#s4">1.2</linkHtml>)</item>
                        </list>
                        <paragraph>*This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="0ca7e5cd-b41a-424e-a76c-4b67ebd41422"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Advanced Unresectable or Metastatic <content styleCode="italics">NRG1</content> Fusion-Positive Non-Small Cell Lung Cancer
</title>
                     <text>
                        <paragraph>BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion with disease progression on or after prior systemic therapy.</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on overall response rate and duration of response <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s54">14.1</linkHtml>)].</content> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="c2bd874f-818e-4c68-9514-b47d38561cd7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Advanced Unresectable or Metastatic <content styleCode="italics">NRG1</content> Fusion-Positive Pancreatic Adenocarcinoma
</title>
                     <text>
                        <paragraph>BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion with disease progression on or after prior systemic therapy.</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on overall response rate and duration of response <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s55">14.2</linkHtml>)]</content>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="9dfb289a-d11e-4543-8b60-c0a9d72630ff"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20241218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Select patients for treatment with BIZENGRI based on the presence of an <content styleCode="italics">NRG1</content> gene fusion. (<linkHtml href="#s6">2.1</linkHtml>)
</item>
                           <item>Evaluate left ventricular ejection fraction (LVEF) before initiating BIZENGRI. (<linkHtml href="#s7">2.2</linkHtml>)
</item>
                           <item>The recommended dosage of BIZENGRI is 750 mg every 2 weeks until disease progression or unacceptable toxicity. (<linkHtml href="#s8">2.3</linkHtml>)
</item>
                           <item>Administer premedications before each infusion to reduce the risk of infusion-related reactions. (<linkHtml href="#s9">2.4</linkHtml>)
</item>
                           <item>Administer as an intravenous infusion, after dilution, over 4 hours. (<linkHtml href="#s12">2.7</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6">
                     <id root="129fe694-1d4a-4693-9a25-3292442b6f89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Patient Selection
</title>
                     <text>
                        <paragraph>Select patients for treatment with BIZENGRI based on the presence of an <content styleCode="italics">NRG1</content> gene fusion in tumor specimens <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s54">14.1</linkHtml>, <linkHtml href="#s55">14.2</linkHtml>)]</content>.
</paragraph>
                        <paragraph>An FDA-approved test for the detection of <content styleCode="italics">NRG1</content> gene fusions is not currently available.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="d571740b-465d-488a-95e6-b877bad2d0c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Evaluation Before Initiating BIZENGRI
</title>
                     <text>
                        <paragraph>Before initiating BIZENGRI, evaluate left ventricular ejection fraction (LVEF) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="96831eca-5920-4f78-9c9d-bc6123e807bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage of BIZENGRI is 750 mg as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s12">2.7</linkHtml>)].</content>
                           </item>
                           <item>Administer premedications before each BIZENGRI infusion as recommended to reduce the risk of infusion-related reactions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s9">2.4</linkHtml>)]</content>.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="1adb2a10-b6bb-4518-a5ef-3a246b71b342"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Premedications
</title>
                     <text>
                        <paragraph>Prior to each infusion of BIZENGRI, administer premedications to reduce the risk of infusion-related reactions (IRRs) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.1</linkHtml>)] (see <linkHtml href="#t1">TableÂ 1</linkHtml>)</content>.
</paragraph>
                        <table ID="t1" width="100%">
                           <caption>TableÂ 1: Premedications Prior to BIZENGRI Infusions
</caption>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>1</sup> Optional after initial BIZENGRI infusion
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Medication</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Dose</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Route of Administration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Corticosteroid<sup>1</sup>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Dexamethasone (10 mg)
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Oral or intravenous
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Antipyretic
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Acetaminophen (1,000 mg)
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Oral or intravenous
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">H1 Antihistamine
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Dexchlorpheniramine (5 mg)<br/>or other anti-H1 equivalent
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Intravenous<br/>or oral
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="167cbac7-bf52-45cf-ae71-62ad6fb2f68c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications for Adverse Reactions
</title>
                     <text>
                        <paragraph>No dose reduction is recommended for BIZENGRI. The recommended dosage modifications of BIZENGRI for adverse reactions are provided in <linkHtml href="#t2">TableÂ 2</linkHtml>.
</paragraph>
                        <table ID="t2" width="100%">
                           <caption>TableÂ 2: Recommended BIZENGRI Dosage Modifications and Management for Adverse Reactions
</caption>
                           <col width="34.000%" align="left"/>
                           <col width="22.167%" align="left"/>
                           <col width="43.833%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Severity</content>
                                 </td>
                                 <td align="left" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Dose Modifications and Management</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
												Infusion-related reactions (IRRs)/Hypersensitivity/Anaphylactic Reactions
												<br/>
                                    <content styleCode="italics">[seeÂ Warnings and Precautions (<linkHtml href="#s16">5.1</linkHtml>)]</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">â¤ Grade 3 IRR
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Interrupt BIZENGRI infusion if IRR is suspected and monitor patient until reaction symptoms resolve.
</item>
                                       <item>Provide symptomatic treatment as needed.
</item>
                                       <item>Resume the infusion at 50% of the infusion rate at which the reaction occurred. The infusion rate may be escalated if there are no additional symptoms.
</item>
                                       <item>Corticosteroid premedication can be used as necessary for subsequent BIZENGRI infusions <content styleCode="italics">[see Recommended Premedications (<linkHtml href="#s9">2.4</linkHtml>)]</content>.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Grade 4 IRR<br/>or any grade<br/>hypersensitivity/<br/>anaphylactic reaction
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue BIZENGRI.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
												Interstitial Lung Disease (ILD)/Pneumonitis
												<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.2</linkHtml>)]</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Grade 1
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Interrupt BIZENGRI until recovery.
</item>
                                       <item>Consider prompt initiation of corticosteroids when the diagnosis is suspected.
</item>
                                       <item>Resume treatment after resolution.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">â¥ Grade 2
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue BIZENGRI.
</item>
                                       <item>Promptly treat with corticosteroids.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Left Ventricular Dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.3</linkHtml>)]</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">LVEF is 45-49%<br/>and absolute decrease from baseline â¥10%<br/>or<br/>LVEF less than 45%
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Interrupt BIZENGRI.
</item>
                                       <item>Repeat LVEF assessment within 3 weeks.
</item>
                                       <item>If LVEF is less than 45% or LVEF has not recovered to within 10% from baseline, permanently discontinue BIZENGRI.
</item>
                                       <item>If LVEF is 50% or greater or LVEF is 45-49% and recovered to within 10% of baseline, resume BIZENGRI and monitor LVEF every 12 weeks while on treatment and as clinically indicated.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Symptomatic congestive heart failure (CHF)
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue BIZENGRI.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Other Clinically Relevant Adverse Reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s21">6.1</linkHtml>)]</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Grade 3 or 4
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold BIZENGRI until recovery to â¤ Grade 1 or baseline.
</item>
                                       <item>Provide symptomatic treatment as needed.
</item>
                                       <item>Resume treatment after resolution of symptoms.
</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="c23bcab4-9408-4a2a-9f30-36af7fc2f718"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation
</title>
                     <text>
                        <paragraph>Dilute and prepare BIZENGRI for intravenous infusion before administration.
</paragraph>
                        <paragraph>For the initial infusion, prepare BIZENGRI as close to administration time as possible to allow for the possibility of extended infusion time in the event of an infusion-related reaction.
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Check that the BIZENGRI solution is clear to slightly opalescent, colorless to slightly yellow. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if discoloration or visible particles are present.
</item>
                           <item>Withdraw and then discard 37.5 mL 0.9% Sodium Chloride Injection from the 250 mL infusion bag. Only use infusion bags made of polyvinylchloride (PVC), polyolefin or polyolefin/polyamide coextruded plastic.
</item>
                           <item>Withdraw a total of 37.5 mL of BIZENGRI from 2 vials and add it to the infusion bag. The final volume in the infusion bag should be 250 mL. Discard any unused portion left in the vial.
</item>
                           <item>Gently invert the bag to mix the solution. Do not shake.
</item>
                           <item>If not used immediately, store the diluted solution refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) and protect from light after preparation unless the infusion is initiated within 2 hours of preparation.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="2f424733-34ff-4d5a-a540-dacb9a869046"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Administration
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>If the infusion time exceeds the recommended storage time, the infusion bag must be discarded and a new infusion bag prepared to continue the infusion. Diluted BIZENGRI solution must by administered within:<list listType="unordered" styleCode="Circle">
                                 <item>6 hours from end of preparation of infusion solution stored at room temperature [15Â°C to 25Â°C (59Â°F to 77Â°F)]
</item>
                                 <item>28 hours from end of preparation of infusion solution stored refrigerated [2Â°C to 8Â°C (36Â°F to 46Â°F)]
</item>
                              </list>
                           </item>
                           <item>If the diluted BIZENGRI solution has been refrigerated, allow it to reach room temperature (approximately 30 minutes) prior to administration.
</item>
                           <item>Administer diluted BIZENGRI solution <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s11">2.6</linkHtml>)]</content> by intravenous infusion using an infusion set made of either PVC, polyethylene (PE), polyurethane (PUR) or polybutadiene (PB) with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.2 micrometer).
</item>
                           <item>Do not infuse BIZENGRI concomitantly in the same IV line with other agents.
</item>
                           <item>Administer BIZENGRI infusion via a peripheral or central line.
</item>
                           <item>Monitor patients closely for signs and symptoms of infusion-related reactions during BIZENGRI infusion and monitor patients for at least 1 hour following completion of the first BIZENGRI infusion and as clinically indicated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.1</linkHtml>)].</content>
                           </item>
                           <item>Administer intravenous infusion over 4 hours.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="bc1ee4dc-f2e1-45aa-b19b-44301cd8ab3d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Injection: 375 mg/18.75 mL (20 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.
</paragraph>
               </text>
               <effectiveTime value="20241218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 375 mg/18.75 mL (20 mg/mL) in a single-dose vial. (<linkHtml href="#s13">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="2793de03-7ede-48ac-8417-42c70f5ec314"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>None.
</paragraph>
               </text>
               <effectiveTime value="20241218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#s14">4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="60b6cfc4-98c1-4f3b-80c1-64f0d450e155"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20241218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Infusion-Related Reactions (IRR)/Hypersensitivity/Anaphylactic Reactions</content>: Administer BIZENGRI in a setting with emergency resuscitation equipment and staff who are trained to monitor for IRRs and to administer emergency medications. Monitor for signs and symptoms of IRR. Interrupt infusion in patients with â¤ Grade 3 IRRs and administer symptomatic treatment as needed. Resume infusion at a reduced rate after resolution of symptoms. Immediately stop the infusion and permanently discontinue BIZENGRI for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis. (<linkHtml href="#s16">5.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>: Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue BIZENGRI in patients with â¥ Grade 2 ILD/pneumonitis. (<linkHtml href="#s17">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Left Ventricular Dysfunction</content>: Assess LVEF before initiating BIZENGRI and at regular intervals during treatment as clinically indicated. Manage through treatment interruption or discontinuation. Permanently discontinue BIZENGRI in patients with symptomatic congestive heart failure (CHF). (<linkHtml href="#s18">5.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s16">
                     <id root="58ac9ec9-d345-439c-946a-67b085427f21"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Infusion-Related Reactions/Hypersensitivity/Anaphylactic Reactions
</title>
                     <text>
                        <paragraph>BIZENGRI can cause serious and life-threatening infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions. Signs and symptoms of IRR may include chills, nausea, fever, and cough.
</paragraph>
                        <paragraph>In the eNRGy study, 13% of patients experienced IRRs, all were Grade 1 or 2; 91% occurred during the first infusion.  The median time to onset was 63 minutes (range: 13 minutes to 240 minutes) from the start of infusion.
</paragraph>
                        <paragraph>Administer BIZENGRI in a setting with emergency resuscitation equipment and staff who are trained to monitor for IRRs and to administer emergency medications. Monitor patients closely for signs and symptoms of infusion reactions during infusion and for at least 1 hour following completion of first BIZENGRI infusion and as clinically indicated. Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s9">2.4</linkHtml>)].</content> Corticosteroid premedication can be used as necessary for subsequent BIZENGRI infusions.
</paragraph>
                        <paragraph>Interrupt BIZENGRI infusion in patients with â¤ Grade 3 IRRs and administer symptomatic treatment as needed. Resume infusion at a reduced rate after resolution of symptoms <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.5</linkHtml>)].</content> Immediately stop the infusion and permanently discontinue BIZENGRI for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="8028110b-db75-4799-a314-0337a86765c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Interstitial Lung Disease/Pneumonitis
</title>
                     <text>
                        <paragraph>BIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis.
</paragraph>
                        <paragraph>In the eNRGy study <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s21">6.1</linkHtml>)],</content> ILD/pneumonitis occurred in 2 (1.1%) patients treated with BIZENGRI. Grade 2 ILD/pneumonitis (Grade 2) resulting in permanent discontinuation of BIZENGRI occurred in 1 (0.6%) patient.
</paragraph>
                        <paragraph>Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g.,Â dyspnea, cough, fever). Immediately withhold BIZENGRI in patients with suspected ILD/pneumonitis and administer corticosteroids as clinically indicated. Permanently discontinue BIZENGRI if ILD/pneumonitis â¥ Grade 2 is confirmed <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="7f836072-af84-4864-bcbd-f75a0917aeb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Left Ventricular Dysfunction
</title>
                     <text>
                        <paragraph>BIZENGRI can cause left ventricular dysfunction.
</paragraph>
                        <paragraph>Left ventricular ejection fraction (LVEF) decrease occurred with anti-HER2 therapies, including BIZENGRI. Treatment with BIZENGRI has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment.
</paragraph>
                        <paragraph>In the eNRGy study <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s21">6.1</linkHtml>)],</content> Grade 2 LVEF decrease [Grade 2 LVEF decrease (40%-50%; 10 - 19% drop from baseline)] occurred in 2% of evaluable patients. Cardiac failure without LVEF decrease occurred in 1.7% of patients including 1 (0.6%) fatal event.
</paragraph>
                        <paragraph>Before initiating BIZENGRI, evaluate LVEF and monitor at regular intervals during treatment as clinically indicated. For LVEF of less than 45% or less than 50% with absolute decrease from baseline of 10% or greater is confirmed, permanently discontinue BIZENGRI. Permanently discontinue BIZENGRI in patients with symptomatic congestive heart failure (CHF) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="1e758b25-9c2f-4e1f-9acf-dd586c2145e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Embryo-Fetal Toxicity
</title>
                     <text>
                        <paragraph>Based on its mechanism of action, BIZENGRI can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Animal studies have demonstrated that inhibition of HER2 and/or HER3 results in impaired embryo-fetal development, including effects on cardiac, vascular and neuronal development, and embryolethality. Advise patients of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of BIZENGRI. Advise females of reproductive potential to use effective contraception during treatment with BIZENGRI and for 2Â months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>, <linkHtml href="#s36">8.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="a3e69222-2d6e-433d-8ef9-1c000794a0cc"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Infusion-Related Reactions/Hypersensitivity/Anaphylaxis [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s16">5.1</linkHtml>
                        </content>)]
</item>
                     <item>Interstitial Lung Disease/Pneumonitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.2</linkHtml>)]</content>
                     </item>
                     <item>Left Ventricular Dysfunction [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.3</linkHtml>)</content>]
</item>
                     <item>Embryo-Fetal Toxicity [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s19">5.4</linkHtml>)</content>]
</item>
                  </list>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">The most common adverse reactions (â¥ 10%)</content> in patients were diarrhea musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. (<linkHtml href="#s21">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">The most common Grade 3 or 4 laboratory abnormalities (â¥ 2%)</content> were increased GGT, decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased aPTT and increased bilirubin. (<linkHtml href="#s21">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Partner Therapeutics, Inc. at 1-888-479-5385 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s21">
                     <id root="288cc2aa-67b7-417f-9d3e-f43d55548697"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to BIZENGRI as a single agent at 750 mg administered intravenously every 2 weeks until disease progression or unacceptable toxicity in 175 patients with <content styleCode="italics">NRG1</content> gene fusion positive tumors in the eNRGy study. Of these, there were 99 patients with NSCLC, 39 patients with pancreatic adenocarcinoma and 37 patients with other solid tumors <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s54">14.1</linkHtml>, <linkHtml href="#s55">14.2</linkHtml>)]</content>. Among the 175 patients who received BIZENGRI, the median duration of exposure to BIZENGRI was 5.3 months (range: 0.1 to 36), including 45% of patients exposed for at least 6 months and 15% of patients exposed for at least 1 year. In this pooled safety population, the most common (â¥ 10%) adverse reactions were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities (â¥ 2%) were increased GGT, decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased aPTT and increased bilirubin.
</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="s22">
                           <id root="28789117-3498-435c-be5d-ca97d6e9934d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">NRG1
</content>
                                 <content styleCode="underline">Gene Fusion Positive Unresectable or Metastatic NSCLC</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                           <component>
                              <section ID="s23">
                                 <id root="2a304b7e-2149-4597-82be-4b561224c1a7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">eNRGy Study</content>
                                    </paragraph>
                                    <paragraph>The safety of BIZENGRI was evaluated in the eNRGy study in 99 patients with unresectable or metastatic NSCLC with <content styleCode="italics">NRG1</content> gene fusions <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s54">14.1</linkHtml>)].</content> Patients received BIZENGRI as a single agent at 750 mg intravenously every 2 weeks until disease progression or unacceptable toxicity. Among patients who received BIZENGRI, 47% were exposed for 6 months or longer and 17% were exposed for greater than one year.</paragraph>
                                    <paragraph>The median age was 66 years (range: 27 to 88), 54% were 65 years or older; 62% were female; 37% were White, 53% were Asian, 2% were Black or African American; and 1% were Hispanic or Latino.</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 25% of patients who received BIZENGRI. Serious adverse reactions in â¥ 2% of patients included pneumonia (n=4) dyspnea and fatigue (n=2 each). Serious adverse reactions occurring in one patient each were: abdominal pain, acute kidney injury, ascites, bradycardia, carotid artery stenosis, cellulitis, acute cholecystitis, COVID-19, decreased appetite, dehydration, dizziness, dysphagia, hyponatremia, ileus, lymphadenitis, nausea, gastric obstruction, pericardial effusion, pneumonitis, pulmonary hypertension, sepsis, staphylococcal infection, tumor pain, urinary tract infection, viral infection and vomiting. Fatal adverse reactions occurred in 3 (3%) patients and included respiratory failure (n=2) and cardiac failure (n=1).</paragraph>
                                    <paragraph>Permanent discontinuation of BIZENGRI due to an adverse reaction occurred in 3% of patients. Adverse reactions resulting in permanent discontinuation of BIZENGRI included dyspnea, pneumonitis and sepsis (n=1 each).</paragraph>
                                    <paragraph>Dosage interruptions of BIZENGRI due to an adverse reaction, excluding temporary interruptions of BIZENGRI due to infusion-related reactions, occurred in 29% of patients. Adverse reactions leading to dosage interruptions in â¥2% of patients included dyspnea, COVID-19, arrhythmia, increased ALT, increased AST, and pneumonia.</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t3">TableÂ 3</linkHtml> summarizes the adverse reactions in the eNRGy study in patients with <content styleCode="italics">NRG1</content> gene fusion positive unresectable or metastatic NSCLC.</paragraph>
                                    <table ID="t3" width="100%">
                                       <caption>TableÂ 3: Adverse Reactions (â¥10%) in Patients with NRG1 Gene Fusion Positive NSCLC Who Received BIZENGRI in the eNRGy Study </caption>
                                       <colgroup>
                                          <col width="59.700%" align="left"/>
                                          <col width="19.900%" align="left"/>
                                          <col width="20.400%" align="left"/>
                                       </colgroup>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>1</sup> Based on NCI CTCAE v4.03 and MedDRA v26.0</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>2</sup> Includes post-procedural diarrhea</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>3</sup> Includes back pain, pain in extremity, musculoskeletal chest pain, myalgia, arthralgia, non-cardiac chest pain, bone pain, musculoskeletal stiffness, neck pain, spinal pain.</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>4</sup> Includes dyspnea exertional</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>5</sup> Includes productive cough</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>6</sup> Includes asthenia</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>7</sup> Includes breast edema, peripheral edema, face edema</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>8</sup> Includes eczema, erythema, dermatitis, dermatitis contact, rash maculopapular, rash erythematous.</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>9</sup> Includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting. AEs that were considered IRRs were counted under the composite term âIRRâ, irrespective of the reported PT.</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="bottom">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <content styleCode="bold">
                                                   <sup>1</sup>
                                                </content>
                                             </td>
                                             <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="bottom">
                                                <content styleCode="bold">BIZENGRI<br/>(N=99)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">
                                                <content styleCode="bold">All Grades<br/>%</content>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">
                                                <content styleCode="bold">Grade 3 or 4<br/>%</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Diarrhea<sup>2</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">25</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">2</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Nausea</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">10</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="bottom">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Musculoskeletal pain<sup>3</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">
                                                <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom"/>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Dyspnea<sup>4</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">18</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Cough<sup>5</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">15</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Fatigue<sup>6</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">17</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">2</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Edema<sup>7</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">11</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Rash<sup>8</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">14</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Infusion-related reactions <sup>9</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">12</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Decreased appetite</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">11</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">1</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Clinically relevant adverse reactions in &lt;10% of patients receiving BIZENGRI were stomatitis (7%), vomiting (8%), cardiac failure and pneumonitis (2% each).</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t4">TableÂ 4</linkHtml> summarizes the laboratory abnormalities in the eNRGy study in patients with <content styleCode="italics">NRG1</content> gene fusion positive unresectable or metastatic NSCLC.</paragraph>
                                    <table ID="t4" width="100%">
                                       <caption>TableÂ 4: Select Laboratory Abnormalities â¥ 20% that Worsened from Baseline in Patients with NRG1 Gene Fusion Positive NSCLC Who Received BIZENGRI in the eNRGy Study </caption>
                                       <colgroup>
                                          <col width="49.000%" align="left"/>
                                          <col width="25.500%" align="left"/>
                                          <col width="25.500%" align="left"/>
                                       </colgroup>
                                       <tfoot>
                                          <tr styleCode="First Last">
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>1</sup> The denominator used to calculate the rate varied from 93 to 96 based on the number of patients with a baseline value and at least one post-treatment value.</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="bottom">
                                                <content styleCode="bold">Laboratory Abnormality</content>
                                             </td>
                                             <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="bottom">
                                                <content styleCode="bold">BIZENGRI</content>
                                                <content styleCode="bold">
                                                   <sup>1</sup>
                                                </content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">
                                                <content styleCode="bold">All Grades<br/>%</content>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">
                                                <content styleCode="bold">Grade 3 or 4<br/>%</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="bottom">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Decreased hemoglobin</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">35</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">4.2</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="middle">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Increased alanine aminotransferase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">30</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">3.1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Decreased magnesium</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">28</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">4.3</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Increased alkaline phosphatase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">27</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Decreased phosphate</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">26</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">1.1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Increased gamma-glutamyl transpeptidase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Increased aspartate aminotransferase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">22</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">3.1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Decreased potassium</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">21</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">2.1</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph/>
                                 </text>
                                 <effectiveTime value="20250307"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s24">
                           <id root="164ffb41-5353-4c11-af3b-e8783eb2a344"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">NRG1
</content>
                                 <content styleCode="underline">Gene Fusion Positive Unresectable or Metastatic Pancreatic Adenocarcinoma</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                           <component>
                              <section ID="s25">
                                 <id root="b4a8a913-2ad0-4b18-93ff-7143032a676e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">eNRGy Study</content>
                                    </paragraph>
                                    <paragraph>The safety of BIZENGRI was evaluated in the eNRGy study in 39 patients with unresectable or metastatic pancreatic adenocarcinoma with <content styleCode="italics">NRG1</content> gene fusions <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s55">14.2</linkHtml>)].</content> Patients received BIZENGRI as a single agent at 750 mg intravenously every 2 weeks until disease progression or unacceptable toxicity. Among patients who received BIZENGRI, 50% were exposed for 6 months or longer and 13% were exposed for greater than one year.</paragraph>
                                    <paragraph>The median age was 51 years (range: 21 to 74), 23% were 65 years or older; 49% were female; 82% were White, 13% were Asian, 2.6% were Black or African American; and 5% were Hispanic or Latino.</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 23% of patients who received BIZENGRI. Serious adverse reactions occurring in one patient each were: anemia, thrombocytopenia, tachycardia, abdominal pain, hemorrhoidal hemorrhage, nausea, cholestatic jaundice, COVID-19, liver abscess, traumatic fracture, blood creatinine increased, back pain, myelodysplastic syndrome, and respiratory disorder. There were 2 fatal adverse reactions, one due to COVID-19 and one due to respiratory failure.</paragraph>
                                    <paragraph>Dosage interruptions of BIZENGRI due to an adverse reaction, excluding temporary interruptions of BIZENGRI due to infusion-related reactions, occurred in 33% of patients. Adverse reactions leading to dosage interruptions in â¥2% of patients included COVID-19, pneumonia, increased AST, neutropenia, abdominal pain, agitation, increased blood alkaline phosphatase, increased blood bilirubin, constipation, increased creatinine, hemorrhage, hyperbilirubinemia, cholestatic jaundice, tachycardia, traumatic fracture, and upper respiratory infection.</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t5">Table 5</linkHtml> summarizes the adverse reactions in the eNRGy study in patients with <content styleCode="italics">NRG1</content> gene fusion positive pancreatic adenocarcinoma.</paragraph>
                                    <table ID="t5" width="100%">
                                       <caption>Table 5: Adverse Reactions (â¥10%) in Patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma Who Received BIZENGRI in the eNRGy Study </caption>
                                       <colgroup>
                                          <col width="38.767%" align="left"/>
                                          <col width="30.633%" align="left"/>
                                          <col width="30.600%" align="left"/>
                                       </colgroup>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>1</sup> Based on NCI CTCAE v4.03 and MedDRA v26.0</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>2</sup> Includes back pain, pain in extremity, musculoskeletal chest pain, myalgia, arthralgia, non-cardiac chest pain, bone pain, musculoskeletal stiffness, neck pain, spinal pain</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>3</sup> Includes asthenia</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>4</sup> Includes peripheral edema, face edema, localized edema, peripheral swelling</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>5</sup> Includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>6</sup> Includes epistaxis, hematochezia, hematuria, hemorrhoidal hemorrhage</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="bottom">
                                                <content styleCode="bold">Adverse Reaction</content>
                                                <content styleCode="bold">
                                                   <sup>1</sup>
                                                </content>
                                             </td>
                                             <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="top">
                                                <content styleCode="bold">BIZENGRI</content>
                                                <br/>
                                                <content styleCode="bold">(N=39)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Rrule" align="center" valign="middle">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">
                                                <content styleCode="bold">Grade 3 or 4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Diarrhea</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">36</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Nausea</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Vomiting</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">2.6</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Abdominal pain</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">18</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Constipation</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">15</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Abdominal distension</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">13</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Stomatitis</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">10</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Musculoskeletal pain<sup>2</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">28</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">2.6</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Fatigue<sup>3</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">21</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Edema<sup>4</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">13</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  Pyrexia</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="bottom">10</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Infections and infestations</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  COVID-19</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">18</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Infusion-related reactions<sup>5</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">15</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Vascular disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Hemorrhage<sup>6</sup>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">13</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Psychiatric disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Anxiety</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">10</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="justify" valign="bottom">Â  Â  Â  Dry skin</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">10</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Clinically relevant adverse reactions in &lt;10% of patients receiving BIZENGRI were decreased appetite (5%), and rash (8%) [including dermatitis acneiform, erythema, dermatitis, dermatitis contact, rash maculopapular, rash erythematous].</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t6">TableÂ 6</linkHtml> summarizes the laboratory abnormalities in the eNRGy study in patients with <content styleCode="italics">NRG1</content> gene fusion positive pancreatic adenocarcinoma.</paragraph>
                                    <table ID="t6" width="100%">
                                       <caption>TableÂ 6: Select Laboratory Abnormalities â¥ 20% That Worsened from Baseline in Patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma Who Received BIZENGRI in the eNRGy Study </caption>
                                       <colgroup>
                                          <col width="49.016%" align="left"/>
                                          <col width="25.975%" align="left"/>
                                          <col width="25.008%" align="left"/>
                                       </colgroup>
                                       <tfoot>
                                          <tr styleCode="First Last">
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="First Footnote">
                                                   <sup>1</sup> The denominator used to calculate the rate varied from 35 to 39, based on the number of patients with a baseline value and at least one post-treatment value.</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="bottom">
                                                <content styleCode="bold">Laboratory Abnormality</content>
                                             </td>
                                             <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="top">
                                                <content styleCode="bold">BIZENGRI</content>
                                                <content styleCode="bold">
                                                   <sup>1</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">(N=39)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">
                                                <content styleCode="bold">All Grades</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                             </td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">
                                                <content styleCode="bold">Grade 3 or 4</content>
                                                <br/>
                                                <content styleCode="bold">(%)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased alanine aminotransferase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">51</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased aspartate aminotransferase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">31</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased bilirubin</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">31</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased phosphate</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">31</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">2.9</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased alkaline phosphatase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">28</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">8</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased sodium</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">28</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">10</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased albumin</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">26</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased potassium</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">26</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">2.6</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased magnesium</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">24</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">2.6</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased gamma-glutamyl transpeptidase</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">15</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased platelets</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">26</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">10</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased hemoglobin</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">23</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">10</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Decreased leukocytes</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">21</td>
                                             <td styleCode="Botrule Rrule" align="center" valign="top">2.6</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph/>
                                 </text>
                                 <effectiveTime value="20250307"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="7e778188-f816-4095-b5f6-f297a77deee4"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Females and Males of Reproductive Potential</content>: Verify pregnancy status of females prior to initiation of BIZENGRI. (<linkHtml href="#s36">8.3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s27">
                     <id root="fc02e99b-8a57-4d10-959a-0c8511e53c17"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="s28">
                           <id root="4dec4891-c01c-4b22-80d2-6b5120b4bdda"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on its mechanism of action, BIZENGRI can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s44">12.1</linkHtml>)]</content>. There are no available data on the use of BIZENGRI in pregnant women to inform a drug-associated risk.</paragraph>
                              <paragraph>Animal studies have demonstrated that HER2 and/or HER3 deficiency results in embryo-fetal malformation, including effects on cardiac, vascular and neuronal development, and embryolethality <content styleCode="italics">(see <linkHtml href="#s31">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>Human IgG1 is known to cross the placenta; therefore, BIZENGRI has the potential to be transmitted from the mother to the developing fetus. Advise patients of the potential risk to a fetus.</paragraph>
                              <paragraph>There are clinical considerations if BIZENGRI is used in pregnant women, or if a patient becomes pregnant within 2 months after the last dose of BIZENGRI (<content styleCode="italics">see <linkHtml href="#s29">Clinical Considerations</linkHtml>)</content>.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s29">
                           <id root="c0c6b1cf-48a9-4ccd-bd3c-576672e6ca8a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                           <component>
                              <section ID="s30">
                                 <id root="d4f5761c-c6e8-4db1-9a3e-fca40cc4b44b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Monitor women who received BIZENGRI during pregnancy or within 2 months prior to conception for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241218"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s31">
                           <id root="5aac0cbc-5df2-44fd-a215-d531122e9776"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                           <component>
                              <section ID="s32">
                                 <id root="ff41204a-b5e9-49a1-a5c4-58b1751e249d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>There are no available data on the use of BIZENGRI in pregnant women. In literature reports in pregnant women receiving a HER2-directed antibody, cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported. These case reports described oligohydramnios in pregnant women who received HER2-directed antibody alone or in combination with chemotherapy. In some case reports, amniotic fluid index increased after use of a HER2-directed antibody was stopped.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241218"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s33">
                                 <id root="2307a1c8-8845-4f07-8822-14a90ce5b1ce"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>There were no animal reproductive or developmental toxicity studies conducted with zenocutuzumab-zbco. A literature-based assessment of the effects on reproduction demonstrated that HER2 and HER3 are critically important in embryo-fetal development. HER2 knockout mice or mice expressing catalytically inactive HER2 die at mid-gestation due to cardiac dysfunction. HER2 knockout mice have also shown abnormal sympathetic nervous system development. In HER3-deficient mice, embryolethality occurred on embryonic day 13.5 due to cardiac and vascular defects, as well as abnormalities in other organs (neural crest, pancreas, stomach, and adrenal). In addition, HER3 is shown to be involved in mammary gland ductal morphogenesis in mice. Zenocutuzumab-zbco can cause embryo-fetal toxicity based on its mechanism of action.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241218"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="7255e237-8fc3-476d-98b9-40f5fc7cc728"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20241218"/>
                     <component>
                        <section ID="s35">
                           <id root="ac21dafb-b1f2-47f4-9eeb-8b80162399b1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of zenocutuzumab-zbco in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG1 is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to BIZENGRI are unknown. Consider the developmental and health benefits of breast feeding along with the mother's clinical need for BIZENGRI treatment and any potential adverse effects on the breastfed child from BIZENGRI or from the underlying maternal condition. This consideration should also take into account the elimination half-life of zenocutuzumab-zbco and washout period of 2 months.
</paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s36">
                     <id root="a7aca5a4-379a-4d4c-83a1-c118afc613eb"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <text>
                        <paragraph>BIZENGRI can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                     <component>
                        <section ID="s37">
                           <id root="0f6b66e2-b367-4ba3-9f1b-efcef829c632"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating BIZENGRI <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s38">
                           <id root="7c918405-ac79-4397-8b38-d3a22104764c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                           <component>
                              <section ID="s39">
                                 <id root="222a28e3-a891-417e-9e2b-487d0f7b174f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise female patients of reproductive potential to use effective contraception during treatment with BIZENGRI and for 2 months after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241218"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s40">
                     <id root="88c03365-95cd-481d-a54a-761149280bd9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of BIZENGRI have not been established in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="66bdb8fa-4785-48bf-a3c5-67136779f138"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Of the 175 patients with <content styleCode="italics">NRG1</content> gene fusion positive tumors in the eNRGy study treated with BIZENGRI at 750 mg every 2 weeks, 75 patients (43%) were 65 years of age or older and 26Â patients (15%) were 75 years of age and older. No clinically important differences in safety or efficacy were observed between patients who were â¥65 years of age and younger patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="948f766f-5cab-4c13-8b6f-b7a79fc141a1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Zenocutuzumab-zbco is a low-fucose humanized full-length immunoglobulin G1 (IgG1) bispecific HER2- and HER3-directed antibody. It has a molecular weight of approximately 146Â kDa and is produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology.
</paragraph>
                  <paragraph>BIZENGRI is a sterile, clear to slightly opalescent, colorless to slightly yellow, preservative-free injection for intravenous infusion in single-dose vials. The pH is 6.0. Each BIZENGRI vial contains 375 mg/18.75 mL zenocutuzumab-zbco at a concentration of 20 mg/mL. Each vial also contains the following inactive ingredients: histidine (34.9 mg), L-histidine hydrochloride monohydrate (51.1 mg), polysorbate 20 (3.7 mg), trehalose (1412 mg), and water for injection.
</paragraph>
               </text>
               <effectiveTime value="20241218"/>
            </section>
         </component>
         <component>
            <section ID="s43">
               <id root="dfbeb464-34af-4b1d-9b85-0cf251a323b0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20241218"/>
               <component>
                  <section ID="s44">
                     <id root="eb02ca77-2bdb-45f0-bdd7-2135aaa6d310"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Zenocutuzumab-zbco is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing <content styleCode="italics">NRG1</content> binding to HER3. Zenocutuzumab-zbco decreased cell proliferation and signaling through the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. In addition, zenocutuzumab-zbco mediates antibody-dependent cellular cytotoxicity (ADCC). Zenocutuzumab-zbco showed antitumor activity in mouse models of <content styleCode="italics">NRG1</content> fusion-positive lung and pancreatic cancers.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s45">
                     <id root="b142d4ff-dd77-406a-9a6c-dd5b74715784"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>The exposure-response relationship and time-course of pharmacodynamic response for zenocutuzumab-zbco have not been fully characterized.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s46">
                     <id root="88b31635-58d3-4ba9-bd1d-a5eb9e330c3f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>Zenocutuzumab-zbco pharmacokinetic parameters are expressed as mean unless otherwise specified. Zenocutuzumab-zbco exposure increases proportionally over a dose range from 480 mg (0.6 times the approved recommended dosage) to 900Â mg (1.2 times the approved recommended dosage). The median time to steady state of zenocutuzumab-zbco concentrations is 8 weeks and the median accumulation ratio is 1.6-fold at the approved recommended dosage.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                     <component>
                        <section ID="s47">
                           <id root="5b6c86b0-9b01-4948-bf9a-b50b5a244ad1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Zenocutuzumab-zbco volume of distribution is 6 L (CV 18%).
</paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s48">
                           <id root="56b4c423-dce3-4a39-af14-fc1cff5f338c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The steady state zenocutuzumab-zbco half-life is 8 days (SD Â±1.3 days) with a clearance of 22 mL/h (CV 37%).
</paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                           <component>
                              <section ID="e48">
                                 <id root="a5808b9d-c191-49e1-813a-17582111ca00"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Zenocutuzumab-zbco is expected to be metabolized into small peptides by catabolic pathways.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241218"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="8f33a2d9-8fc6-468d-9622-a2a05701a38f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of zenocutuzumab-zbco were observed based on age (22 to 88 years), sex, race [White or Asian], body weight (38 to 126 kg), albumin level (20 to 49 g/L), mild or moderate renal impairment (creatinine clearance (CLcr) 30 to 89 mL/min), and mild hepatic impairment (total bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN).
</paragraph>
                              <paragraph>The pharmacokinetics of zenocutuzumab-zbco in patients with moderate to severe hepatic impairment (total bilirubin &gt; 1.5 to 3 times ULN with any AST) or severe renal impairment (CLcr &lt; 30 mL/min) is unknown.
</paragraph>
                           </text>
                           <effectiveTime value="20241218"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="75b962a8-4095-4442-a466-949d19ebf63a"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity
</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparison of the incidence of anti-drug antibodies in the studies below with the incidence of anti-drug antibodies in other studies, including those of BIZENGRI or of other zenocutuzumab products.
</paragraph>
                        <paragraph>In patients who received BIZENGRI at the approved recommended dosage for up to 30 months, 7 of 153 (4.6%) patients developed anti-zenocutuzumab antibodies. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and efficacy of zenocutuzumab is unknown.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s51">
               <id root="be9dd407-87ad-44d6-8310-7a8edefcb256"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20241218"/>
               <component>
                  <section ID="s52">
                     <id root="2776914f-d085-4da1-a9e2-fcf4133600c5"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>No studies have been performed to assess the carcinogenic or mutagenic potential of zenocutuzumab-zbco.
</paragraph>
                        <paragraph>Animal fertility studies have not been conducted with zenocutuzumab-zbco.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s53">
               <id root="de8e117c-1139-4627-805d-6ec9b06986be"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="s54">
                     <id root="fc64dbbf-65bc-49a1-b832-ca07cb77421c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Advanced Unresectable or Metastatic <content styleCode="italics">NRG1</content> Fusion-Positive Non-Small Cell Lung Cancer
</title>
                     <text>
                        <paragraph>The efficacy of BIZENGRI was evaluated in the eNRGy study (<linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT02912949">NCT02912949</linkHtml>) a multicenter, open-label, multi-cohort clinical study. The study enrolled adult patients with advanced or metastatic <content styleCode="italics">NRG1</content> fusion-positive NSCLC who had disease progression following standard of care treatment for their disease. Identification of positive <content styleCode="italics">NRG1</content> gene fusion status was prospectively determined based on next generation sequencing (NGS) assays performed at local laboratories or central laboratories. Patients received BIZENGRI as an intravenous infusion, 750 mg every 2 weeks, until unacceptable toxicity or disease progression. Tumor assessments were performed every 8 weeks. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) as determined by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Efficacy was evaluated in 64 patients with <content styleCode="italics">NRG1</content> fusion-positive NSCLC previously treated with systemic therapy enrolled in eNRGy.</paragraph>
                        <paragraph>The trial population characteristics were: median age 63.5 years (range: 32 to 86) with 47% of patients â¥ 65 years of age; 64% female; 56% Asian, 33% White, and 11% other races or not reported; none were Hispanic or Latino; baseline ECOG performance status of 0 or 1 (97%) or 2 (3%) and 98% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range 1 to 6); 95% had prior platinum chemotherapy and 64% had prior anti-PD-1/PD-L1 therapy. A total of 54 patients (84%) had an <content styleCode="italics">NRG1</content> gene fusion detected by RNA-based NGS that may include DNA sequencing and 9 (14%) had an <content styleCode="italics">NRG1</content> gene fusion detected by DNA-based NGS.</paragraph>
                        <paragraph>Efficacy results are summarized in <linkHtml href="#t7">Table 7</linkHtml> and <linkHtml href="#t8">Table 8</linkHtml>.</paragraph>
                        <table ID="t7" width="100%">
                           <caption>Table 7: Efficacy Results for Advanced Unresectable or Metastatic NRG1 Fusion-Positive NSCLC in the eNRGy Study </caption>
                           <colgroup>
                              <col width="52.900%" align="left"/>
                              <col width="47.100%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup> Confirmed overall response rate assessed by BICR</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>2</sup> Based on observed duration of response</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">BIZENGRI</content>
                                    <br/>
                                    <content styleCode="bold">Previously Treated with Systemic Therapy</content>
                                    <br/>
                                    <content styleCode="bold">(n = 64)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Overall response rate<sup>1</sup> (95% CI)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">33% (22%, 46%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Complete response rate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.6%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Partial response rate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">31%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule" align="left" valign="top">Duration of response</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Median (95% CI) (months)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7.4 (4.0, 16.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Patients with DOR â¥6 months<sup>2</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">43%</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t8" width="100%">
                           <caption>Table 8: Efficacy Results by NRG1 Gene Fusion Partner in NRG1 Fusion-Positive NSCLC Patients in the eNRGy Study </caption>
                           <colgroup>
                              <col width="21.844%" align="left"/>
                              <col width="25.245%" align="left"/>
                              <col width="13.843%" align="left"/>
                              <col width="15.623%" align="left"/>
                              <col width="23.445%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup> Fusion partners identified in this primary analysis set (n=64) may not represent all potential fusion partners.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">PR=partial response; PD=progressive disease; NA=not applicable; â+â indicates ongoing response-</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="top">
                                    <content styleCode="Bold Italics">NRG1 </content>
                                    <content styleCode="bold">Partner</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" rowspan="2" align="center" valign="top">
                                    <content styleCode="bold">BIZENGRI</content>
                                    <br/>
                                    <content styleCode="bold">(n = 64)</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="top">
                                    <content styleCode="bold">ORR</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">DOR</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">n (%)</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">95% CI</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Range (Months)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">CD74</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">37</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">12 (32)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(18, 50)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.8+; 20.3+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">SLC3A2</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">14</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">5 (36)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(13, 65)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.6; 20.8+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">SDC4</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2 (29)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(3.7, 71)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7.4; 16.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">CDH1</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1 (50)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(1.3, 99)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.9+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">FUT10</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">PVALB</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">ST14</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">VAMP2</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PR</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">5.6</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="s55">
                     <id root="217eba31-01e2-4586-b604-c2c35a83d8c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Advanced Unresectable or Metastatic <content styleCode="italics">NRG1</content> Fusion-Positive Pancreatic Adenocarcinoma
</title>
                     <text>
                        <paragraph>The efficacy of BIZENGRI was evaluated in the eNRGy study (<linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT02912949">NCT02912949</linkHtml>), a multicenter, open-label, multi-cohort clinical study. The study enrolled 30 adult patients with advanced or metastatic <content styleCode="italics">NRG1</content> fusion-positive pancreatic adenocarcinoma who had disease progression following standard of care treatment. Identification of an <content styleCode="italics">NRG1</content> gene fusion was prospectively determined in local laboratories using next generation sequencing (NGS). Patients received BIZENGRI as an intravenous infusion, 750 mg every 2 weeks, until unacceptable toxicity or disease progression. Tumor assessments were performed every 8 weeks. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) as determined by a blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</paragraph>
                        <paragraph>The trial population characteristics were: median age 49 years (range: 21 to 72) with 10% of patients â¥ 65 years of age; 43% female; 87% White, 7% Asian, 3.3% Black or African American, and 3.3% other races or not reported; 3.3% were Hispanic or Latino; baseline ECOG performance status of 0 (53%) or 1 (47%) and all patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range 0 to 5); 97% had prior systemic therapy with FOLFIRINOX, gemcitabine/taxane-based therapy, or both. A total of 27Â patients (90%) had an <content styleCode="italics">NRG1</content> gene fusion detected by RNA-based NGS that may include DNA sequencing and 3 (10%) had an <content styleCode="italics">NRG1</content> gene fusion detected by DNA-based NGS.</paragraph>
                        <paragraph>Efficacy results are summarized in <linkHtml href="#t9">Table 9</linkHtml> and <linkHtml href="#t10">Table 10</linkHtml>.</paragraph>
                        <table ID="t9" width="100%">
                           <caption>Table 9: Efficacy Results for Advanced Unresectable or Metastatic NRG1 Fusion-Positive Pancreatic Adenocarcinoma in the eNRGy Study </caption>
                           <colgroup>
                              <col width="55.700%" align="left"/>
                              <col width="44.300%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup> Confirmed overall response rate assessed by BICR</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>2</sup> Based on observed duration of response</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">BIZENGRI</content>
                                    <br/>
                                    <content styleCode="bold">(n = 30)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Overall response rate<sup>1</sup> (95% CI)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">40% (23%, 59%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Complete response rate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.3%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Partial response rate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">37%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule" align="left" valign="top">Duration of response</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Range (months)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.7, 16.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Patients with DOR â¥6 months<sup>2</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">67%</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t10" width="100%">
                           <caption>Table 10: Efficacy Results by NRG1 Gene Fusion Partner in NRG1 Fusion-Positive Pancreatic Adenocarcinoma Patients in the eNRGy Study </caption>
                           <colgroup>
                              <col width="22.016%" align="left"/>
                              <col width="19.956%" align="left"/>
                              <col width="19.016%" align="left"/>
                              <col width="16.997%" align="left"/>
                              <col width="22.016%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup> Fusion partners identified in this primary analysis set (n=30) may not represent all potential fusion partners.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">PR=partial response; PD=progressive disease; SD=stable disease; NA=not applicable; â+âÂ indicates ongoing response</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" rowspan="2" align="left" valign="top">
                                    <content styleCode="Bold Italics">NRG1 </content>
                                    <content styleCode="bold">Partner</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" rowspan="2" align="center" valign="top">
                                    <content styleCode="bold">BIZENGRI</content>
                                    <br/>
                                    <content styleCode="bold">(n = 30)</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" colspan="2" align="center" valign="top">
                                    <content styleCode="bold">ORR</content>
                                 </td>
                                 <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">DOR</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">n (%)</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">95% CI</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Range (Months)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">ATP1B1</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">14</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7 (50)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(23, 77)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.7, 16.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">CD44</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(0, 71)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">NOTCH2</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1 (33)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(0.8, 91)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7.4+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">SLC4A4</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2 (67)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">(9, 99)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7.5+, 15.2+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">AGRN</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PR</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">9.1+</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">APP</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PR</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">CDH1</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">SD, SD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">SDC4</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">SD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">THBS1</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">PD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="italics">VTCN1</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">SD</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="a4324a84-572c-47f7-aca5-d9335c5eec68"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="s57">
                     <id root="f5ab6f89-ab73-4b5d-bab7-ac049d1aff88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>BIZENGRI (zenocutuzumab-zbco) injection is a sterile, clear to slightly opalescent, colorless to slightly yellow, preservative-free solution for intravenous infusion. Each single-dose vial contains 375 mg/18.75 mL (20 mg/mL) BIZENGRI. Two vials (equivalent to 1 dose) are packed in a single carton. (NDC 71837-1000-1 for individual vial and NDC 71837-1000-2 for a single carton).</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="cd965b02-e461-4e1a-a33d-e6a71d9ba3b5"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store in a refrigerator at 2Â°C to 8Â°C (36Â°F to 46Â°F) in original carton to protect from light. Do not freeze. Do not shake.
</paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s59">
               <id root="c137ed69-f623-4552-b5f9-c496c9f38b9b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).
</paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="s60">
                     <id root="23a20754-c106-4f1f-ae66-c3c661743673"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion-Related Reactions/Hypersensitivity/Anaphylaxis</content>
                        </paragraph>
                        <paragraph>Advise patients that BIZENGRI can cause serious and life-threatening infusion-related reactions (IRRs). Advise patients to alert their healthcare provider immediately for any signs or symptoms of IRRs during and following the infusion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="s61">
                     <id root="e4951a08-f165-4c98-a004-b8a5fe367f39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>
                        </paragraph>
                        <paragraph>Inform patients that BIZENGRI can cause serious and life threatening ILD/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="a2726a6c-71c8-47b0-8626-b3b5770c2331"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Left Ventricular Dysfunction</content>
                        </paragraph>
                        <paragraph>Inform patients that BIZENGRI can cause serious and life threatening left ventricular dysfunction. Advise patients to immediately contact their healthcare provider for new or worsening cardiovascular symptoms <content styleCode="italics">[seeÂ Warnings and Precautions (<linkHtml href="#s18">5.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="s63">
                     <id root="9417cf9e-17d2-4974-b962-424d998a6ef3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Inform female patients of the potential risk to a fetus. Advise female patients to contact their healthcare provider with a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.4</linkHtml>), Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>)]</content>.</item>
                           <item>Advise females of reproductive potential to use effective contraception during treatment with BIZENGRI and for 2 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s27">8.1</linkHtml>, <linkHtml href="#s36">8.3</linkHtml>)]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="11a2594d-9647-488b-81c7-58c40938c796"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with BIZENGRI and for 2 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s34">8.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Manufactured by: Partner Therapeutics, Inc. Lexington, MA 02421</paragraph>
                        <paragraph>BIZENGRI<sup>Â®</sup> is a registered trademark of Merus N.V.</paragraph>
                        <paragraph>U.S. License Number 2087</paragraph>
                        <paragraph>Â©2025 Partner Therapeutics, Inc.</paragraph>
                        <paragraph>AW028-01</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="d1">
               <id root="4eaa6700-2481-4b10-88c4-aa3314df2ee2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title/>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col width="50.000%" align="left"/>
                        <col width="50.000%" align="left"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td align="left" valign="top">
                              <paragraph styleCode="First Footnote">This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph styleCode="First Footnote">Issued: Mar/2025</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center" valign="top">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>BIZENGRIÂ® (bi zen gree)<br/>(zenocutuzumab-zbco)<br/>injection, for intravenous use</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left" valign="top">
                              <paragraph ID="p01">
                                 <content styleCode="bold">What is the most important information I should know about BIZENGRI?</content>
                              </paragraph>
                              <content styleCode="bold">BIZENGRI may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infusion-related, allergic and anaphylactic reactions.</content> BIZENGRI may cause serious infusion-related and allergic reactions that can be life-threatening. Infusion-related reactions are also common during BIZENGRI treatment. Before each BIZENGRI infusion, your healthcare provider will give you medicines to help reduce your chance of getting infusion-related reactions. Your healthcare provider will monitor you for signs and symptoms during your infusion and for at least 1 hour after your first infusion and as needed. Tell your healthcare provider right away if you develop any of the following signs or symptoms during or after your BIZENGRI infusion:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>chills or shaking</item>
                                 <item>nausea, vomiting, or diarrhea</item>
                                 <item>fever</item>
                                 <item>cough</item>
                                 <item>sudden swelling of your face, tongue, throat, or troubled swallowing</item>
                                 <item>throat tightness or discomfort</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>itching or rash</item>
                                 <item>shortness of breath or wheezing</item>
                                 <item>chest discomfort</item>
                                 <item>feeling light-headed</item>
                                 <item>dizziness</item>
                                 <item>back or neck pain</item>
                                 <item>feeling of numbness or tingling</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Lung problems.</content> BIZENGRI may cause serious lung problems that may be life-threatening. If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>trouble breathing</item>
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>cough</item>
                                 <item>fever</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Heart problems that may affect your heart's ability to pump blood.</content> BIZENGRI may cause serious and life-threatening heart problems that may lead to death. Your healthcare provider will check your heart function before you start treatment with BIZENGRI and as needed during your treatment. Tell your healthcare provider right away if you develop any new or worsening symptoms of heart problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>shortness of breath</item>
                                 <item>coughing</item>
                                 <item>tiredness</item>
                                 <item>swelling of your feet, ankles or legs</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>irregular heartbeat</item>
                                 <item>sudden weight gain</item>
                                 <item>dizziness or feeling light-headed</item>
                                 <item>loss of consciousness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">Your healthcare provider will check you for these side effects during your treatment with BIZENGRI and may delay your treatment, slow the infusion rate, or completely stop your treatment with BIZENGRI if you develop severe side effects.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Harm to your unborn baby.Â </content>Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with BIZENGRI.<paragraph>
                                       <content styleCode="bold">Females who are able to become pregnant:</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with BIZENGRI.</item>
                                       <item>Use effective birth control (contraception) during treatment and for 2 months after your last dose of BIZENGRI.</item>
                                    </list>
                                 </item>
                              </list>See <content styleCode="bold">â<linkHtml href="#p02">What are the possible side effects of BIZENGRI?</linkHtml>â</content> for more information about side effects.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">What is BIZENGRI?</content>
                              <br/>BIZENGRI is a prescription medicine used to treat adults who have:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>lung cancer called non-small cell lung cancer (NSCLC):<list listType="unordered" styleCode="Circle">
                                       <item>that has a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), <content styleCode="bold">and</content>
                                       </item>
                                       <item>whose disease has worsened on or after prior cancer treatment.</item>
                                    </list>
                                 </item>
                                 <item>pancreatic cancer called pancreatic adenocarcinoma:<list listType="unordered" styleCode="Circle">
                                       <item>that has a neuregulin 1 (<content styleCode="italics">NRG1</content>) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), <content styleCode="bold">and</content>
                                       </item>
                                       <item>whose disease has worsened on or after prior cancer treatment.</item>
                                    </list>
                                 </item>
                              </list>It is not known if BIZENGRI is safe and effective in children.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Before receiving BIZENGRI, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have lung or breathing problems other than your lung cancer.</item>
                                 <item>have or have had any heart problems.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if BIZENGRI passes into your breast milk. Do not breastfeed during treatment and for 2 months after your last dose of BIZENGRI.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">How will I receive BIZENGRI?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>BIZENGRI will be given to you by your healthcare provider as an intravenous (IV) infusion into your vein, usually over 4 hours.</item>
                                 <item>BIZENGRI is usually given 1 time every 2 weeks.</item>
                                 <item>Your healthcare provider will decide how many treatments you will need.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left" valign="top">
                              <paragraph ID="p02">
                                 <content styleCode="bold">What are the possible side effects of BIZENGRI?</content>
                              </paragraph>
                              <content styleCode="bold">BIZENGRI may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">â<linkHtml href="#p01">What is the most important information I should know about BIZENGRI?</linkHtml>â</content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of BIZENGRI include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>diarrhea</item>
                                 <item>muscle or bone pain</item>
                                 <item>tiredness</item>
                                 <item>nausea</item>
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>rash</item>
                                 <item>constipation</item>
                                 <item>vomiting</item>
                                 <item>stomach-area (abdominal) pain</item>
                                 <item>swelling of your breast, face, ankles or legs</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">The most common severe abnormal blood test results with BIZENGRI include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>increased blood levels of liver enzymes and bilirubin</item>
                                 <item>decreased red blood cell counts and platelet counts</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>decreased blood level of sodium, magnesium, and phosphate</item>
                                 <item>increase in the time that it takes your blood to clot</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">These are not all of the possible side effects of BIZENGRI.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">General information about safe and effective use of BIZENGRI:</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about BIZENGRI that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">What are the ingredients in BIZENGRI?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> zenocutuzumab-zbco<br/>
                              <content styleCode="bold">Inactive ingredients:</content> histidine, L-histidine hydrochloride monohydrate, polysorbate 20, trehalose, and water for injection<br/>Manufactured by: Partner Therapeutics, Inc. Lexington, MA 02421<br/>BIZENGRIÂ® is a registered trademark of Merus N.V.<br/>U.S. License Number 2087<br/>Â© 2025 Partner Therapeutics, Inc.<br/>For more information call 1-888-479-5385<br/>AW029-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="s65">
               <id root="a6397c17-d798-4d88-90fc-60bdc71ce1b6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel â 750 mg Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 71837-1000-2</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BizengriÂ®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">zenocutuzumab-zbco<br/>Injection 750 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">375 mg/18.75 mL<br/>(20 mg/mL) per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Infusion After Dilution</paragraph>
                  <paragraph>Each carton contains:</paragraph>
                  <paragraph>Two 375 mg/18.75 mL single-dose vials. Discard unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="mm01"/> + <renderMultiMedia referencedObject="mm02"/> = one 750 mg dose</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PTx</content>
                  </paragraph>
                  <paragraph>PARTNER<br/>THERAPEUTICS</paragraph>
                  <renderMultiMedia referencedObject="mm03"/>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="biz00-0001-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm02">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="biz00-0001-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm03">
                     <text>Principal Display Panel â 750 mg Carton Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="biz00-0001-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>